MJMG Holdings Inc (DBA Custom Biologics)
SARS-CoV-2 Point of Care Test Development — This project is to develop and qualify a rapid Point-of-Care diagnostic test for the SARS-CoV-2 virus that causes Covid-19. The test will be run on a portable reader that will be capable of operating in a clinic or in the field using a battery power source.